SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+6.45%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$412M
AUM Growth
+$412M
(+5.3%)
Cap. Flow
-$4.63M
Cap. Flow
% of AUM
-1.12%
Top 10 Holdings %
Top 10 Hldgs %
58.04%
Holding
34
New
6
Increased
9
Reduced
14
Closed
4
Top Buys
| 1 |
Pfizer
PFE
|
$31.5M |
| 2 |
CVS Health
CVS
|
$17.3M |
| 3 |
Medtronic
MDT
|
$8.83M |
| 4 |
Bio-Rad Laboratories Class A
BIO
|
$7.62M |
| 5 |
Illumina
ILMN
|
$5.65M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$19.5M |
| 2 |
Becton Dickinson
BDX
|
$18.6M |
| 3 |
Bristol-Myers Squibb
BMY
|
$15.2M |
| 4 |
Cardinal Health
CAH
|
$10.1M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
$9.43M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Medtronic
MDT
$119B
| $35.8M | 8.7% | 435,075 +107,172 | +33% | +$8.83M |
|
|
2
Pfizer
PFE
$141B
| $31.5M | 7.64% | +1,093,416 | New | +$31.5M |
|
|
3
Gilead Sciences
GILD
$140B
| $31M | 7.52% | 382,362 -240,761 | -39% | -$19.5M |
|
4
Biogen
BIIB
$19.4B
| $26.5M | 6.42% | 102,234 -2,052 | -2% | -$531K |
|
5
Incyte
INCY
$16.5B
| $25M | 6.07% | 398,699 -33,846 | -8% | -$2.13M |
|
|
6
Bristol-Myers Squibb
BMY
$96B
| $19.2M | 4.66% | 374,687 -297,093 | -44% | -$15.2M |
|
7
GE HealthCare
GEHC
$33.7B
| $19.1M | 4.64% | 247,531 +17,942 | +8% | +$1.39M |
|
|
8
CVS Health
CVS
$92.8B
| $17.3M | 4.2% | +219,000 | New | +$17.3M |
|
9
Zimmer Biomet
ZBH
$21B
| $17.2M | 4.17% | 141,218 -17,851 | -11% | -$2.17M |
|
|
10
Cardinal Health
CAH
$35.5B
| $16.6M | 4.02% | 164,305 -99,831 | -38% | -$10.1M |
|
11
Centene
CNC
$14.3B
| $16.1M | 3.9% | 216,416 -6,732 | -3% | -$500K |
|
12
Tenet Healthcare
THC
$16.3B
| $14.6M | 3.54% | 193,279 +35,304 | +22% | +$2.67M |
|
13
Edwards Lifesciences
EW
$47.8B
| $14.3M | 3.47% | 187,556 -25,439 | -12% | -$1.94M |
|
14
Elevance Health
ELV
$71.8B
| $13.1M | 3.18% | 27,807 -13,340 | -32% | -$6.29M |
|
15
Baxter International
BAX
$12.7B
| $12.7M | 3.08% | 328,132 +134,889 | +70% | +$5.21M |
|
16
Globus Medical
GMED
$8.27B
| $12.5M | 3.03% | 234,374 +12,547 | +6% | +$669K |
|
17
Labcorp
LH
$23.1B
| $11.5M | 2.8% | 50,686 -14,171 | -22% | -$3.22M |
|
18
Bruker
BRKR
$5.16B
| $9.35M | 2.27% | 127,312 +23,957 | +23% | +$1.76M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.2B
| $8.32M | 2.02% | 86,247 -9,801 | -10% | -$945K |
|
20
Qiagen
QGEN
$10.1B
| $8.28M | 2.01% | 190,539 +89,826 | +89% | +$3.9M |
|
|
21
Bio-Rad Laboratories Class A
BIO
$8.06B
| $7.62M | 1.85% | +23,609 | New | +$7.62M |
|
22
Ionis Pharmaceuticals
IONS
$6.79B
| $7.34M | 1.78% | 145,012 -20,604 | -12% | -$1.04M |
|
23
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.14M | 1.49% | 32,092 -20,876 | -39% | -$4M |
|
24
Acadia Pharmaceuticals
ACAD
$4.38B
| $5.89M | 1.43% | 188,111 +8,326 | +5% | +$261K |
|
|
25
Illumina
ILMN
$15.8B
| $5.65M | 1.37% | +40,592 | New | +$5.65M |
|